

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) with Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (WAVE T1D)



WAVE T1D

Purpose of the Study:

- This study is being done in people with newly diagnosed Type 1 Diabetes (T1D). We want to see if using a treatment called Anti-thymocyte Globulin (ATG), followed by either Adalimumab or Verapamil, can help people keep making insulin for a longer time which may also help to control blood glucose.

You may be eligible to participate if you:

- Have been **recently diagnosed with T1D** and can start the treatment phase within 6 months of your diagnosis.
- Are between **9 and 20 years old**.
- Weigh more than **66lbs**.
- Can read and understand **English or Spanish**
- Are up-to-date on recommended vaccines for your age and willing to avoid certain live vaccines during the study
- Use only insulin to control blood sugar (no other glucose-lowering medicines)

Participation Includes:

- Being in the study for up to **3 years**
- About **12 office visits** and at least **6 scheduled phone contacts**.
- **2 ATG Infusions**
- **Biweekly under-the-skin (subcutaneous) injections** (adalimumab or placebo) OR **Taking a daily pill** (verapamil or placebo)
- Wearing a **Continuous Glucose Monitor (CGM)**
- **Physical Exams**
- **Electrocardiograms (ECGs)**
- **Blood Draws** for lab tests
- **Daily Insulin Recording**
- **Mixed Meal Tolerance Test (MMTT)**
- **Abstinence or use of highly effective form of birth control**

*Participants will be compensated per visit, ATG Infusion, and MMTT

If you are interested in participating or have questions, please contact:

[Name of Site]

[Site Staff Name]

[Contact Information]

